
Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2024-2030
Description
Hemoglobinopathies Market by Indication (Sickle Cell Disease, Thalassemia), Treatment (Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy), Diagnosis, End-User - Global Forecast 2024-2030
The Hemoglobinopathies Market size was estimated at USD 2.63 billion in 2023 and expected to reach USD 2.79 billion in 2024, at a CAGR 33.02% to reach USD 19.46 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hemoglobinopathies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemoglobinopathies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hemoglobinopathies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories Inc., Biogen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CRISPR Therapeutics AG, Danaher Corporation, Emmaus Life Sciences Inc., Gamida Cell Ltd., Genetix Biotech Asia Pvt. Ltd, Laboratory Corporation, Medunik USA Inc., Merck & Co. Inc., Nexcelom Bioscience LLC, Novartis AG, PerkinElmer Inc., Pfizer, Inc., Prolong Pharmaceuticals, LLC, Regenacy Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sebia, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sysmex Corporation, and Vertex Pharmaceuticals Incorporated.
Market Segmentation & Coverage
This research report categorizes the Hemoglobinopathies Market to forecast the revenues and analyze trends in each of the following sub-markets:
Indication
Sickle Cell Disease
Thalassemia
Alpha Thalassemia
Beta thalassemia
Treatment
Blood Transfusion
Bone Marrow & Stem Cell Transplant
Chemotherapy
Curative Therapy
Gene Therapy
Hydroxyurea
Iron Chelation Therapy
Diagnosis
Genetic Testing
Haemoglobin Isoelectric Focusing (Hb IEF)
Haemoglobin Solubility Test
Hemoglobin by High Performance Liquid Chromatography
Hemoglobin electrophoresis (Hb ELP)
Routine Red Blood Cell (RBC) Count
End-User
Clinics
Diagnostic Laboratories
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Hemoglobinopathies Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemoglobinopathies Market?
3. What are the technology trends and regulatory frameworks in the Hemoglobinopathies Market?
4. What is the market share of the leading vendors in the Hemoglobinopathies Market?
5. Which modes and strategic moves are suitable for entering the Hemoglobinopathies Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Hemoglobinopathies Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of common rare blood-related diseases
- 5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
- 5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with hemoglobinopathies treatment
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
- 5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness about hemoglobinopathies therapies
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Hemoglobinopathies Market, by Indication
- 6.1. Introduction
- 6.2. Sickle Cell Disease
- 6.3. Thalassemia
- 6.4.1. Alpha Thalassemia
- 6.4.2. Beta thalassemia
- 7. Hemoglobinopathies Market, by Treatment
- 7.1. Introduction
- 7.2. Blood Transfusion
- 7.3. Bone Marrow & Stem Cell Transplant
- 7.4. Chemotherapy
- 7.5. Curative Therapy
- 7.6. Gene Therapy
- 7.7. Hydroxyurea
- 7.8. Iron Chelation Therapy
- 8. Hemoglobinopathies Market, by Diagnosis
- 8.1. Introduction
- 8.2. Genetic Testing
- 8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
- 8.4. Haemoglobin Solubility Test
- 8.5. Hemoglobin by High Performance Liquid Chromatography
- 8.6. Hemoglobin electrophoresis (Hb ELP)
- 8.7. Routine Red Blood Cell (RBC) Count
- 9. Hemoglobinopathies Market, by End-User
- 9.1. Introduction
- 9.2. Clinics
- 9.3. Diagnostic Laboratories
- 9.4. Hospitals
- 10. Americas Hemoglobinopathies Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Hemoglobinopathies Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Hemoglobinopathies Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Alnylam Pharmaceuticals, Inc.
- 14.1.3. Bio-Rad Laboratories Inc.
- 14.1.4. Biogen Inc.
- 14.1.5. Bluebird Bio, Inc.
- 14.1.6. Bristol Myers Squibb
- 14.1.7. CRISPR Therapeutics AG
- 14.1.8. Danaher Corporation
- 14.1.9. Emmaus Life Sciences Inc.
- 14.1.10. Gamida Cell Ltd.
- 14.1.11. Genetix Biotech Asia Pvt. Ltd
- 14.1.12. Laboratory Corporation
- 14.1.13. Medunik USA Inc.
- 14.1.14. Merck & Co. Inc.
- 14.1.15. Nexcelom Bioscience LLC
- 14.1.16. Novartis AG
- 14.1.17. PerkinElmer Inc.
- 14.1.18. Pfizer, Inc.
- 14.1.19. Prolong Pharmaceuticals, LLC
- 14.1.20. Regenacy Pharmaceuticals, Inc.
- 14.1.21. Sangamo Therapeutics, Inc.
- 14.1.22. Sanofi S.A.
- 14.1.23. Sebia
- 14.1.24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
- 14.1.25. Sysmex Corporation
- 14.1.26. Vertex Pharmaceuticals Incorporated
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
- FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
- FIGURE 3. HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
- FIGURE 7. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 8. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
- FIGURE 10. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
- FIGURE 12. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 14. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.